Celltrion Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Celltrion is de winst gegroeid met een gemiddeld jaarlijks percentage van 1.6%, terwijl de Biotechs industrie de winst jaarlijks groeide met 1.6%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 14.5% per jaar. Het rendement op eigen vermogen van Celltrion is 1.1%, en het heeft een nettomarge van 6.5%.

Belangrijke informatie

1.6%

Groei van de winst

0.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.7%
Inkomstengroei	14.5%
Rendement op eigen vermogen	1.1%
Nettomarge	6.5%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Mar 25

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Opbrengsten en kosten

Hoe Celltrion geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

KOSE:A068270 Opbrengsten, kosten en inkomsten (KRW Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	2,876,253	187,097	762,997	161,112
30 Jun 24	2,666,611	323,331	610,011	161,112
31 Mar 24	2,315,848	392,826	407,846	161,112
31 Dec 23	2,176,432	535,648	198,356	161,112
30 Sep 23	2,304,473	603,795	196,472	139,714
30 Jun 23	2,277,818	542,616	179,966	139,714
31 Mar 23	2,350,070	582,780	183,631	139,714
31 Dec 22	2,283,967	526,616	204,971	139,714
30 Sep 22	2,376,733	566,168	220,603	125,769
30 Jun 22	2,133,015	543,369	217,022	125,769
31 Mar 22	1,967,894	482,930	194,374	125,769
31 Dec 21	1,893,401	569,488	180,730	125,769
30 Sep 21	1,788,695	564,777	175,444	171,437
30 Jun 21	1,935,547	597,615	167,273	171,437
31 Mar 21	1,933,237	608,477	150,937	171,437
31 Dec 20	1,849,116	517,760	126,626	171,437
30 Sep 20	1,733,144	512,182	148,229	113,568
30 Jun 20	1,473,428	402,929	140,896	113,568
31 Mar 20	1,279,603	342,041	141,114	113,568
31 Dec 19	1,128,460	301,030	131,592	113,568
30 Sep 19	988,284	230,443	144,915	108,060
30 Jun 19	930,333	225,180	131,754	108,060
31 Mar 19	958,797	228,480	126,670	108,060
31 Dec 18	982,075	245,755	113,897	108,060
30 Sep 18	1,013,790	308,254	132,375	79,660
30 Jun 18	1,014,774	355,009	131,874	79,660
31 Mar 18	997,483	381,655	125,612	79,660
31 Dec 17	949,080	368,222	112,701	79,660
30 Sep 17	883,631	308,461	94,727	87,856
30 Jun 17	819,814	263,666	78,505	87,856
31 Mar 17	758,701	215,812	65,778	87,856
31 Dec 16	670,581	158,958	75,517	87,856
30 Sep 16	630,045	176,699	96,722	37,320
30 Jun 16	631,225	181,015	88,835	37,320
31 Mar 16	614,243	179,605	84,306	37,320
31 Dec 15	603,413	154,090	66,696	37,320
30 Sep 15	534,991	117,389	44,620	69,642
30 Jun 15	470,682	70,144	52,551	69,642
31 Mar 15	481,797	84,083	66,040	69,642
31 Dec 14	471,046	112,676	64,767	69,642
30 Sep 14	373,936	97,604	82,928	25,386
30 Jun 14	349,650	118,987	62,678	25,386
31 Mar 14	232,292	83,007	39,321	17,804
31 Dec 13	226,208	102,455	25,241	25,386

Kwaliteitswinsten: A068270 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (6.5%) A068270 } zijn lager dan vorig jaar (26.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van A068270 is de afgelopen 5 jaar met 1.6% per jaar gegroeid.

Versnelling van de groei: De winstgroei A068270 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: A068270 had het afgelopen jaar een negatieve winstgroei ( -69% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Biotechs ( -1.3% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 1.1% ) van A068270 wordt als laag beschouwd.

Celltrion Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024

Consensus EPS estimates fall by 16%

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases

Consensus EPS estimates fall by 21%

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?